Achieving pCR is therefore one of the main objectives of NAC but occurs only in a minority of patients, with 30–50% of pCR in TNBC, 50–80% in HER2-positive breast cancer and 5–20% in high-grade luminal cancers. This evidence concerns the gene ERBB2 and cancer.